Valuations are at record highs, thanks to strong IPO exits, broader economic recovery, and growing participation by nontraditional investors. Don’t sell yourself short—your company may well be worth far more than your balance sheet would indicate.
Regulation A+ may finally be starting to get the media exposure it deserves. This story includes Cityzenith ‘s Reg A+ raise mentioned side-by-side with celebrity-backed venture funds.
Here’s another example of how individual investors in the online equity market (such as Reg A+) use different criteria than traditional VCs. It’s an unwritten rule that VCs don’t want to see more than 2 or 3 founders. But individual startup investors don’t seem to be bothered by that.
U.S. startups founded solely by females raised just $3.2 billion in 2020, a billion less than the previous year. This isn’t for lack of trying — there wasn’t a downturn in the numbers of female founders pitching for funding.
With the democratization of the capital markets, Main Street investors are wanting to find out how to get in on all the various opportunities that Wall Street investors have access to.
It was almost a billion-dollar week for life sciences IPOs last week, following a Q1 for IPOs overall that we haven’t seen since the tech bubble in 2000.
If you were hoping for a SPAC deal to come along to fund your startup, don’t hold your breath. One seemingly small change in accounting guidance from the SEC has triggered an almost complete shutdown of the enthusiasm for SPACs.
One of the key drivers shaping the industry: new financing structures are emerging as viable options. The traditional angel/VC route is no longer the only option for the substantial capital raises needed for R&D and clinical trials.
Another one that’s given up control and the lion’s share of the rewards of their company. 7% to Y Combinator. 41.33%(!) in their 2017 seed round.
Health Diagnostic Startups Raised Record $4.8B In 2020
Are diagnostic companies harder to get funded than therapeutics? Harder or not, there’s no shortage of funding for diagnostics, even post-pandemic.